Active	Status	Sponsor type	Region	Phase	Filter
3 Active 7 Inactive 10 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Duytschaever, Mattias
OCEAN, NCT02168829: Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial	Active, not recruiting	4	1284	Europe, Canada, RoW	Rivaroxaban, Xarelto, Acetylsalicylic acid, Aspirin, ASA	Ottawa Heart Institute Research Corporation, Canadian Institutes of Health Research (CIHR), Bayer, Biotronik Canada Inc	Atrial Fibrillation, Stroke	07/25	08/25
PSOT, NCT03481413: Patient Specific Optimized Therapy Post-Market Clinical Follow-up Study	Terminated	N/A	566	Europe, US, RoW	Ablation	EPD Solutions, A Philips Company	Arrythmia	03/23	03/23
AVANT GUARD, NCT06096337: Pulsed Field Ablation (PFA) Vs Anti-Arrhythmic Drug (AAD) Therapy As a First Line Treatment for Persistent Atrial Fibrillation	Recruiting	N/A	520	Europe, Canada, US, RoW	FARAPULSE™ Pulsed Field Ablation (PFA) System, Anti-Arrhythmic Drug (AAD): Flecainide, Sotalol, Propafenone, Dofetilide, and Dronedarone	Boston Scientific Corporation	Persistent Atrial Fibrillation	12/25	12/27